Capricor Therapeutics Inc Stock Price, News & Analysis

Capricor Therapeutics (NASDAQ: CAPR) announced a publication demonstrating enhanced potency of cell therapies through specific signaling pathway manipulation. Collaborating with Cedars-Sinai Medical Center, the study highlighted the upregulation of beta-catenin and downregulation of CD90 as key factors in cell line consistency and potency. The findings link therapeutic efficacy to microRNAs in exosomes, supporting Capricor's advances in exosome-based therapeutics for diseases such as Duchenne muscular dystrophy. The company plans further pipeline expansion announcements in mid-2021.

Capricor Therapeutics has partnered with Lonza to enhance the manufacturing of its leading cell therapy candidate, CAP-1002, aimed at treating Duchenne Muscular Dystrophy (DMD) and complications from COVID-19. The collaboration will leverage Lonza’s expertise to support the scale-up process, crucial for late-stage clinical trials and potential commercialization. CAP-1002 has received orphan drug designation from the FDA and has shown promising results in phase 2 trials. Manufacturing operations will commence at Lonza's Houston center.

Capricor Therapeutics (NASDAQ: CAPR) announced that the independent Data and Safety Monitoring Board (DSMB) has approved the continuation of its Phase II clinical trial assessing CAP-1002 for severe COVID-19 treatment. The DSMB's safety review found no significant issues, allowing the trial, which includes up to 60 patients, to proceed. CAP-1002 aims to mitigate the cytokine storm, a severe inflammatory response in COVID-19 patients. Initial case data suggest promise for CAP-1002 in addressing cardiac complications associated with COVID-19, with results expected in H1 2021.

Capricor Therapeutics (NASDAQ: CAPR) announced the initiation of its Phase 2 INSPIRE trial for CAP-1002, focusing on treating severe COVID-19 patients. The first two patients have been dosed, with the study set to enroll up to 60 participants requiring supplemental oxygen. CAP-1002 utilizes allogeneic cardiosphere-derived cells to target the cytokine storm associated with COVID-19. This trial aims to assess the safety and efficacy of the treatment, particularly for patients facing high risks of morbidity or cardiac complications linked to COVID-19.

Capricor Therapeutics (NASDAQ: CAPR) announced positive preclinical data for a multivalent exosome-mRNA vaccine targeting COVID-19, demonstrating long-lasting immunity to multiple SARS-CoV-2 proteins. The company is expanding its exosome platform technology while advancing its CAP-1002 program for Duchenne Muscular Dystrophy. In Q3 2020, Capricor reported a net loss of approximately $3.9 million, with cash and marketable securities totaling $35.3 million. The company aims to initiate patient enrollment in upcoming clinical studies and explore partnerships to enhance its pipeline.

Capricor Therapeutics (NASDAQ: CAPR) announced positive preclinical results for its novel exosome-based mRNA vaccine for COVID-19, developed in collaboration with Johns Hopkins University. The vaccine shows potential in inducing long-lasting immunity to multiple SARS-CoV-2 proteins. Key findings include a safe exosome formulation that delivers functional mRNA and generates persistent cellular immune responses. Capricor plans to schedule a pre-IND meeting with the FDA to discuss clinical development strategies. The company reported a net loss of approximately $3.9 million for Q3 2020 with $35.3 million in cash on hand.

Capricor Therapeutics (NASDAQ: CAPR) will announce its third-quarter financial results for 2020 after market close on November 12, 2020. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide a business update.

Capricor focuses on developing cell and exosome-based therapeutics, with its lead candidate, CAP-1002, targeting Duchenne muscular dystrophy and COVID-19 cytokine storms. The company is also exploring exosome vaccines for COVID-19.

On September 23, 2020, Capricor Therapeutics (NASDAQ: CAPR) announced that it will present data from the Phase II HOPE-2 clinical trial for its lead product CAP-1002, targeting Duchenne muscular dystrophy (DMD), at the World Muscle Society Virtual Congress on October 1. The trial showed significant improvements in upper limb, cardiac, and respiratory functions after 12 months of treatment, with p-values less than 0.05. CEO Dr. Linda Marbán emphasized the importance of this therapy for DMD patients, as treatment options remain limited and a pathway for potential FDA approval is under discussion.

Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, announced that CEO Linda Marbán, Ph.D., will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 10:30 AM ET. Capricor specializes in first-in-class cell and exosome-based therapeutics aimed at treating diseases such as Duchenne muscular dystrophy and COVID-19. The presentation will be accessible via webcast, providing insights into the company's innovative approaches and ongoing clinical developments.